Sorafenib

• Sorafenib is a Tyrosine kinase inhibitors with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases

• It became the first clinically approved molecular targeted drug for the treatment of HCC and displayed a satisfactory effect in improving overall survival (OS) rates and progression-free survival (PFS) of patients

  • Now ?second line given IMbrave150 Trial
    • Unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either Atezolizumab plus Bevacizumab or Sorafenib
    • Overall survival at 12 months was 67.2% with atezolizumab–bevacizumab and 54.6% with sorafenib